Status:
COMPLETED
Thrombin Generation Values and Percutaneous Coronary Intervention Results.
Lead Sponsor:
HaEmek Medical Center, Israel
Conditions:
Coagulation Disorder
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Brief Summary
Cardiovascular diseases are the most common cause of death in the western world. Myocardial infarction pathogenesis usually involves the development of an atherosclerotic plaque and thrombus. Past re...
Detailed Description
The aim of our study is to investigate the correlation of thrombin generation values using calibrated automated thrombogram and cardiac catheterization results in active ischemic heart disease patient...
Eligibility Criteria
Inclusion
- Acute coronary syndrome: ST segment elevation myocardial infraction, unstable angina, non ST elevation myocardial infraction or patients presented with chest pain suspect for acute coronary syndrome .
- planned percutaneous coronary intervention.
- ability to give Informed consent.
Exclusion
- Acute coronary syndrome in the last 6 month prior to current event.
- thrombophilia
- pregnancy
- liver failure or cirrhosis
- anticoagulant current use
- active cancer
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT03391622
Start Date
April 1 2018
End Date
August 30 2020
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hemek medical center
Afula, Israel, 1834111